5 Small-cap Stocks under spotlight – MXC, IPD, NEU, ESH and WBT

MGC PHARMACEUTICALS LTD (ASX: MXC) – MXC has recently received Human Research Ethics Committee approval to conduct a Phase II clinical trial into the benefits of CogniCann, in partnership with the Institute for Health Research at the University of Notre Dame, for dementia and Alzheimer patients. The current cash and cash equivalent stands at $9.859 million as at June 30, 2018 quarter. The stock was trading at a market price of $0.054 and with a daily price change of -$0.001 and a percentage change of -1.818% as at August 29, 2018. The stock has however, undergone a performance change of a 19.57% over the past 12 months. The EPS is still on a negative side -0.011 AUD and currently there is no dividend history to the stock.

IMPEDIMED LIMITED (ASX: IPD) – The potential applications for BIS-generated healthcare metrics are very extensive and are likely to become a key element for managing a wide variety of patients. Besides this, subscription revenue now accounts for 10% of the company’s quarterly medical revenue, (up from over 3% as compared to the prior corresponding period (PCP)). Total Contract Value (TCV) substantially increased by 111% to $1.9 Mn in Q4FY18 from the previous quarter while Contracted Revenue Pipeline (CRP) grew by 75% to $3.5 Mn during the same period over the pcp. The stock was trading at a market price of $0.500 and with a daily price change of $0.010 and a percentage change of 2.041% as at August 29, 2018. The stock has however, undergone a performance change of a -21.60% over the past 12 months. The EPS is still on a negative side -0.077 AUD and there are no dividends declared.

NEUREN PHARMACEUTICALS LIMITED (ASX: NEU) – Lately, the company and ACADIA Pharmaceuticals Inc. signed an exclusive North American License Agreement for the development and commercialization of trofinetide for Rett syndrome and other indications. NEU has retained the rights to develop and commercialize trofinetide for all indications outside of North America. As per the License Agreement, the company will receive US $10 million upfront plus potential milestones of up to US $455 million and royalties. The stock was trading at a market price of $1.135 and with a daily price change of $0.095 and a percentage change of 9.135% as at August 29, 2018 which is near its 52-week low. The stock has however, undergone a performance change of -13.33% over the past 12 months. The EPS is on a negative side -0.019 AUD which impacts the profits of its shareholders.

ESPORTS MOGUL ASIA PACIFIC LIMITED (ASX: ESH) – For the Thailand Dota 2 qualifiers for Singtel’s PVP Esports Championship, Mogul Arena is the platform provider. It’s estimated that there are currently 2.2 billion gamers across all platforms globally, and ‘Esports’ is one of the fastest growing industries in the world with the total video game market size was estimated to be US$116 billion in 2017. The stock was trading at a market price of $0.022 and with a daily price change of -$0.003 and a percentage change of -12% as at August 29, 2018. The stock has however, undergone a performance change of 47.06% over the past 12 months. The EPS is on a negative side -0.009 AUD which is associated to the profits of its shareholders and there is no dividend history for the stock.

WEEBIT NANO LTD (ASX: WBT) – For the business the priority is to sign first cooperation agreement with a key industry player in Q4 2018. Estimated at USD $60 billion the company is targeting the non-volatile memory market. As of August 2018, the cash in hand of the company is at A$3.36 million. The company forecast significant growth with the emerging memory technologies. The stock was trading at a market price of $0.047 and with a daily price change of -$0.004 and a percentage change of -7.843% as at August 29, 2018. The stock has however, undergone a performance change of attractive 155.00% over the past 12 months. The EPS is though on a negative side -0.002 AUD and there is no dividend history for this stock.

Sponsored ad by Kalkine

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here